ATE277616T1 - Synergistische kombination von roflumilast und pde-3 hemmern - Google Patents

Synergistische kombination von roflumilast und pde-3 hemmern

Info

Publication number
ATE277616T1
ATE277616T1 AT00927094T AT00927094T ATE277616T1 AT E277616 T1 ATE277616 T1 AT E277616T1 AT 00927094 T AT00927094 T AT 00927094T AT 00927094 T AT00927094 T AT 00927094T AT E277616 T1 ATE277616 T1 AT E277616T1
Authority
AT
Austria
Prior art keywords
pde
sub
roflumilast
inhibitors
synergistic combination
Prior art date
Application number
AT00927094T
Other languages
English (en)
Inventor
Hermann Amschler
Rolf Beume
Dietrich Haefner
Christian Schudt
Armin Hatzelmann
Ulrich Kilian
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE277616T1 publication Critical patent/ATE277616T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00927094T 1999-05-04 2000-04-27 Synergistische kombination von roflumilast und pde-3 hemmern ATE277616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108808 1999-05-04
PCT/EP2000/003838 WO2000066123A1 (en) 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor

Publications (1)

Publication Number Publication Date
ATE277616T1 true ATE277616T1 (de) 2004-10-15

Family

ID=8238107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927094T ATE277616T1 (de) 1999-05-04 2000-04-27 Synergistische kombination von roflumilast und pde-3 hemmern

Country Status (11)

Country Link
US (2) US6498173B1 (de)
EP (1) EP1176960B1 (de)
JP (1) JP2002543133A (de)
AT (1) ATE277616T1 (de)
AU (1) AU4558800A (de)
CA (1) CA2372850C (de)
DE (1) DE60014353T2 (de)
ES (1) ES2228512T3 (de)
PT (1) PT1176960E (de)
SI (1) SI1176960T1 (de)
WO (1) WO2000066123A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289961A1 (de) * 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituiertes benzamid-dichloropyridinyl-n-oxid als pde4 inhibitor
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
EP1889620A4 (de) * 2005-06-09 2008-12-10 Santen Pharmaceutical Co Ltd Roflumilast enthaltende augentropfen
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929208D0 (en) 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses

Also Published As

Publication number Publication date
AU4558800A (en) 2000-11-17
DE60014353D1 (de) 2004-11-04
WO2000066123A1 (en) 2000-11-09
CA2372850A1 (en) 2000-11-09
DE60014353T2 (de) 2005-10-13
EP1176960A1 (de) 2002-02-06
SI1176960T1 (en) 2005-04-30
EP1176960B1 (de) 2004-09-29
PT1176960E (pt) 2005-02-28
US6897229B2 (en) 2005-05-24
US20030050329A1 (en) 2003-03-13
US6498173B1 (en) 2002-12-24
CA2372850C (en) 2011-01-18
ES2228512T3 (es) 2005-04-16
JP2002543133A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
DK1202986T3 (da) Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
DE60014353D1 (de) Synergistische kombination von roflumilast und pde-3 hemmern
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
AU2483000A (en) Treatment of asthma with mek inhibitors
HUP0000487A2 (hu) Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
NO20014479D0 (no) Fremgangsmåte ved behandling av spiseforstyrrelser
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
MXPA03009750A (es) Compuestos quimicos.
NO20053046D0 (no) 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
ATE225657T1 (de) Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
ZA90878B (en) Arylalkyl-amines and-amides having anticonvulsant and neuroprotective properties
ATE236169T1 (de) Heterocyclisch kondensierte morphinoid-derivate
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
MXPA03004023A (es) Compuestos quimicos.
ATE279924T1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5- dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
SE0103668D0 (sv) Method for the treatment of overactive blader
WO2002067866A3 (en) Piperazine derivatives as metalloprotease inhibitors
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1176960

Country of ref document: EP

EEIH Change in the person of patent owner